If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
1978 Genentech produces biosynthetic human insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly 1981 Novo Nordisk chemically and enzymatically converts porcine to human insulin 1982 Genentech synthetic human insulin (above) approved 1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin 1996 Lilly Humalog "lispro" insulin analogue approved. 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and the EU. 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US. 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US. 2008 Abbott laboratories " FreeStyle Navigator CGM" gets approved. 2013 The US Food and Drug Administration (FDA) requested more cardiac safety tests for Insulin degludec. 2015 Insulin degludec was approved by the FDA in September 2015.
On 15 August 2008, Permskie Novosti reported that a Russian soldier had called home on 10 August and told his mother: "We are there [in South Ossetia] since 7 August. All of our 58th army." On 15 August 2008, Vyatksky krai reported that the sister of soldier Vitaly (who was fighting in South Ossetia) said that her brother called on 6 August and he was going to move [to unknown location]; later, Vitaly told his sister on 7 August that "we are going to the mountains." On 15 August 2008, Komsomolskaya Pravda reported that 19-year-old Onar Aliev from the 19th Motor Rifle Division died in South Ossetia on the night of 8 August during the shelling of Tskhinvali. His mother said her son called for the last time on 4 August and told her that he would participate in the "true exercises" somewhere near Abkhazia. On 15 August 2008, Trud made a report about junior sergeant Aleksandr Sviridov who was killed in South Ossetia. He called his mother on 2 August and said: "There won't be any holiday. There are intensified preparations; we frequently have parachute jumps. Apparently, we will be deployed to somewhere." On 17 August 2008, Komsomolskaya Pravda reported that Aleksandr Plotnikov, the soldier from 693rd Regiment, said that he knew in early August that there would be war when two companies of his regiment were sent to the mountains near Tskhinvali. In August 2008, Life.ru reported that 29-year Aleksey Tarasov, who was killed in action in South Ossetia, was buried in his village.
== History == George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently to make it possible to see platelets for the first time. William Addison in 1842 drew pictures of a platelet-fibrin clot. Lionel Beale in 1864 was the first to publish a drawing showing platelets. Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material. Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultze's spherules (It.) piastrine: little plates. Bizzozero possibly proposed the name Blutplattchen. William Osler observed platelets and, in published lectures in 1886, called them a third corpuscle and a blood plaque; and described them as "a colorless protoplasmic disc". James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication, changing to platelets in his 1910 publication.
Several characters from the series also appeared in Minna Atsumare! Falcom Gakuen, a four-part comedy manga which later saw two short anime adaptations in the mid-2010s. Audio drama adaptations of the games have also been produced, with a few set between the games and filling in details glossed over. Transcripts of two Trails of Cold Steel dramas were translated by Xseed Games and published online as promotional material for Trails of Cold Steel II. A 2.5D musical based on Trails of Cold Steel ran in January 2017. The Legend of Heroes: Trails of Destiny, a tabletop game designed by Promethium Books, was released in 2024. A trading card game by TCG Corporation was released in Japan in November 2024.
Sources: en.wikipedia.org
=== Protein ESI === A major application for ESI is the field of protein mass spectrometry. Here, the MS is used for the identification and sizing of proteins. The identification of a protein sample can be done in an ESI-MS by de novo peptide sequencing (using tandem mass spectrometry) or peptide mass fingerprinting. Both methods require the previous digestion of proteins to peptides, mostly accomplished enzymatically using proteases. As well for the digestion in solution as for the in-gel digestion buffered solutions are needed, whose content in salts is too high and in analyte is too low for a successful ESI-MS measurement. Therefore, a combined desalting and concentration step is performed. Usually a reversed phase liquid chromatography is used, in which the peptides stay bound to the chromatography matrix whereas the salts are removed by washing. The peptides can be eluted from the matrix by the use of a small volume of a solution containing a large portion of organic solvent, which results in the reduction of the final volume of the analyte. In LC-MS the desalting/concentration is realised with a pre-column, in off-line measurements reversed phase micro columns are used, which can be used directly with microliter pipettes. Here, the peptides are eluted with the spray solution containing an appropriate portion of organic solvent. The resulting solution (usually a few microliters) is enriched with the analyte and, after transfer to the spray capillary, can be directly used in the MS.
== Experimental reconstruction == Many research groups are actively attempting experimental reconstruction of the interactions between prebiotic reactions. One major consideration is the ability for these reactions to operate in the same environmental conditions. These one-pot syntheses would likely push the reaction towards specific subgroups of molecules. The key to building proto-metabolic scenarios involves coupling constructive and interconversion reactions. Constructive reactions use autocatalytic prebiotic chemistries to increase the structural complexity of the original molecule, while interconversion reactions connect different prebiotic chemistries by changing the functional groups appended to the original molecule. A functional group is a group of atoms that has similar properties whenever it appears in different molecules. These interconversion reactions and functional group transformations can lead to new prebiotic chemistries and precursor molecules.
No one." Secretary of State Marco Rubio similarly claimed while testifying before Congress that no death resulted from the shutdown. Dr. Brooke Nichols, an infectious disease modeler working at Boston University, created an impact counter to estimate the life toll of funding cuts on various USAID health programs. As of 5 July 2025, the counter estimates that over 341,700 deaths have been caused by the funding discontinuation, over 230,700 of which are children.
=== Dynamic covalent chemistry === In dynamic covalent chemistry covalent bonds are broken and formed in a reversible reaction under thermodynamic control. While covalent bonds are key to the process, the system is directed by non-covalent forces to form the lowest energy structures.
==== Phycoerythrin-like proteins ==== Phycobiliproteins are water soluble light-capturing proteins, produced by cyanobacteria, and several algae. These pigments have been explored as fluorescent tags, food coloring agents, cosmetics, and immunological diagnostic agents. Most of these pigments are synthesized and accumulated intracellularly. As an exception, the cyanobacteria Oscillatoria and Scytonema sp. release an extracellular phycoerythrin-like 250 kDa protein. This pigment inhibits the growth of the green algae Chlorella fusca and Chlamydomonas and can be potentially used as an algicide.
Sources: en.wikipedia.org
== Plot == At the underground Black Mesa Research Facility, the theoretical physicist Gordon Freeman participates in an experiment on a crystal of unknown origin. This triggers a "resonance cascade", which greatly damages the facility and teleports in hostile alien creatures. Eli Vance tells Freeman to get to the surface and find help. After going through several layers of Black Mesa, Freeman discovers that United States Marines and black operators have been dispatched to the facility to terminate the aliens but also to cover up the incident by eliminating all the remaining Black Mesa personnel. A scientist instructs him to make his way to the Lambda Complex to stop the alien invasion. Freeman then discovers a monster called the Tentacle, and kills the giant creature using a rocket engine test facility that incinerates it, and uses an underground monorail to reach a rocket silo. He launches a satellite to help the Lambda team, but is captured by vengeful Marines and left for dead in a trash compactor. Escaping through a waste treatment complex, Freeman travels through a part of Black Mesa filled with alien specimens, collected long before the resonance cascade. Overpowered by the aliens, the Marines withdraw and begin to launch air strikes. Freeman crosses the facility's surface to reach the Lambda Complex, where he discovers secret teleportation technology. There, scientists inform him that a powerful alien creature is preventing them from closing the portal. They teleport him to the alien dimension Xen to kill it.
However, although the notion of obesity as a state of 'leptin resistance' has become ingrained in the minds of many researchers, data does not directly support this contention. For example, the work of Rudolph Leibel at Columbia University shows that, in both obese and lean individuals, leptin injections do not reduce body mass. The finding that both lean and obese subjects have a similar lack of response underscores the notion that the brain is not designed to respond to increased leptin by decreasing food intake; rather, lack of leptin acts as a signal to increase food intake. Indeed, Leibel's work has shown that the decreases in serum leptin that occur post-weight-loss constitute a state of leptin deficiency, which drives increased appetite with weight loss. As such, leptin injections in weight-reduced patients can prevent increases in appetite and thereby allow patients to maintain weight loss. These studies, therefore, demonstrate that leptin treatment may be a useful strategy to treat obesity in humans, if not by driving weight loss directly then by allowing weight loss (as a result of diet and exercise) to be more readily maintained. Moreover, as geneticists learn more from the few cases of leptin gene mutations, the possibility remains that, although leptin was ineffective at treating obesity across the population, some individual obese patients might still benefit from its use as an anti-obesity medication. Research into the adipose-derived hormones adiponectin and resistin is ongoing. Like leptin, these hormones also affect energy balance and metabolism.
Bully: Brett Height: 5'8 Weight: 164 lb Victim(s): Zack Fighter: Abel Cullum Height: 5'7 Weight: 158 lb Money earned by Bully: $1000 Money earned by victim(s): $9000 Original airing: Friday October 4, 2012.
The suspensory muscle of duodenum (also known as suspensory ligament of duodenum, Treitz's muscle or ligament of Treitz) is a thin muscle connecting the junction between the duodenum and jejunum (the small intestine's first and second parts, respectively), as well as the duodenojejunal flexure to connective tissue surrounding the superior mesenteric and coeliac arteries. The suspensory muscle most often connects to both the third and fourth parts of the duodenum, as well as the duodenojejunal flexure, although the attachment is quite variable. The suspensory muscle marks the formal division between the duodenum and the jejunum. This division is used to mark the difference between the upper and lower gastrointestinal tracts, which is relevant in clinical medicine as it may determine the source of gastrointestinal bleeding. The suspensory muscle is derived from mesoderm and plays a role in the embryological rotation of the gut, by offering a point of fixation for the rotating gut. It is also thought to help digestion by widening the angle of the duodenojejunal flexure. Superior mesenteric artery syndrome is a rare abnormality caused by a congenitally short suspensory muscle.
For example, sodium o-phenylphenate-resistant strains are dealt with via formaldehyde fumigation, while imazalil-resistant strains are controlled through the use of pyrimethanil, a fungicide also approved for fighting strains resistant to other fungicides. As fungicide resistance increases globally, other measures of control are being considered, including that of biocontrol. Effective biocontrol agents include bacteria such as Bacillus subtilis, Pseudomonas cepacia, and Pseudomonas syringae as well as fungi such as Debaryomyces hansenii and Candida guilliermondii. In Clementines and Valencia oranges, Candida oleophila, Pichia anomala, and Candida famata have been shown to reduce disease. Despite the ability of various biocontrol agents to exhibit antagonistic activity, biocontrol has not been shown to provide complete control over P.digitatum, and is therefore commonly used in conjunction with another measure of control. Alternative measures of control include essential oils such as Syzygium aromaticum and Lippia javanica, ultraviolet light, gamma-irradiation, X-ray curing, vapour heat, and cell-penetrating anti-fungal peptides.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.